Showing 2811-2820 of 3069 results for "".
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p
- South Florida Women's Shelter Dedicates Shade Structureshttps://practicaldermatology.com/news/south-florida-womens-shelter-dedicates-shades-structures/2460992/Aid to Victims of Domestic Abuse, Inc. (AVDA) in Delray Beach, FL dedicated its new shade structure at the Casa Vegso Residential Campus last month. The structure was funded by an American Academy of Dermatology Shade Structure Grant and SafeSun, Inc., a nonprofit organization dedicated to the pr
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- Golden State Dermatology Adds Concord Practicehttps://practicaldermatology.com/news/golden-state-dermatology-adds-concord-practice/2460850/Curtis A. Raskin, MD, PhD, FAAD and his team are now part of Golden State Dermatology. The clinic in Downtown Concord adds to the eight new locations Golden State added in 2020, after adding eight in 2019. Dr. Raskin received his medical degree and PhD in molecular biology from State Un
- Allergan Aesthetics, Botox Cosmetic Unveil "See Yourself" Campaign with Real Stories from Real Patientshttps://practicaldermatology.com/news/allergan-aesthetics-botox-cosmetic-unveil-see-yourself-campaign-with-real-stories-from-real-patients/2460828/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. Watch 'See Yourself' shorts at www.BotoxCosmetic.com and @Bot
- New Research Shows How Immune Cells Organize Themselves in the Epidermishttps://practicaldermatology.com/news/new-research-shows-how-immune-cells-organize-themselves-in-the-epidermis/2460827/New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. Many people don’t realize that the epidermis is home to immune cells. To bring more cla
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new